Connor, Clark & Lunn Investment Management Ltd. Biomarin Pharmaceutical Inc Transaction History

Connor, Clark & Lunn Investment Management Ltd.

  • $28.9 Billion
  • Q3 2025

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 390,637 shares of BMRN stock, worth $21.4 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
390,637
Previous 403,547 3.2%
Holding current value
$21.4 Million
Previous $22.2 Million 4.63%
% of portfolio
0.07%
Previous 0.09%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 13, 2025
SELL
$52.62 - $61.93 $679,324 - $799,516
-12,910 Reduced 3.2%
390,637 $21.2 Million
Q2 2025

Aug 07, 2025
SELL
$54.08 - $68.32 $6.37 Million - $8.05 Million
-117,802 Reduced 22.6%
403,547 $22.2 Million
Q1 2025

May 12, 2025
BUY
$61.25 - $72.83 $10.1 Million - $12 Million
164,853 Added 46.24%
521,349 $36.9 Million
Q4 2024

Feb 10, 2025
BUY
$61.93 - $70.49 $14.9 Million - $16.9 Million
240,239 Added 206.64%
356,496 $23.4 Million
Q3 2024

Nov 08, 2024
BUY
$69.02 - $93.84 $8.02 Million - $10.9 Million
116,257 New
116,257 $8.17 Million
Q3 2023

Nov 13, 2023
SELL
$85.07 - $94.48 $770,734 - $855,988
-9,060 Reduced 63.13%
5,292 $468,000
Q2 2023

Aug 10, 2023
SELL
$86.68 - $100.3 $18.7 Million - $21.7 Million
-216,114 Reduced 93.77%
14,352 $1.24 Million
Q1 2023

May 09, 2023
SELL
$87.74 - $117.27 $7.67 Million - $10.3 Million
-87,430 Reduced 27.5%
230,466 $22.4 Million
Q4 2022

Feb 10, 2023
BUY
$80.93 - $108.63 $9.43 Million - $12.7 Million
116,511 Added 57.85%
317,896 $32.9 Million
Q3 2022

Nov 10, 2022
SELL
$82.16 - $96.94 $3.76 Million - $4.44 Million
-45,816 Reduced 18.53%
201,385 $17.1 Million
Q2 2022

Aug 05, 2022
BUY
$71.48 - $86.85 $6.53 Million - $7.93 Million
91,298 Added 58.56%
247,201 $20.5 Million
Q1 2022

May 12, 2022
BUY
$74.28 - $92.69 $10.6 Million - $13.2 Million
142,606 Added 1072.47%
155,903 $12 Million
Q4 2021

Feb 10, 2022
SELL
$71.72 - $91.47 $4.16 Million - $5.31 Million
-58,034 Reduced 81.36%
13,297 $1.18 Million
Q3 2021

Nov 12, 2021
BUY
$74.77 - $85.47 $3.79 Million - $4.33 Million
50,623 Added 244.46%
71,331 $5.51 Million
Q2 2021

Aug 12, 2021
BUY
$75.51 - $84.79 $974,834 - $1.09 Million
12,910 Added 165.56%
20,708 $1.73 Million
Q1 2021

May 13, 2021
SELL
$74.73 - $90.69 $1.31 Million - $1.6 Million
-17,594 Reduced 69.29%
7,798 $589,000
Q4 2020

Feb 16, 2021
BUY
$72.61 - $90.2 $1.18 Million - $1.47 Million
16,284 Added 178.79%
25,392 $2.23 Million
Q3 2020

Nov 12, 2020
BUY
$71.87 - $131.03 $99,683 - $181,738
1,387 Added 17.96%
9,108 $693,000
Q2 2020

Aug 13, 2020
SELL
$79.55 - $124.22 $85,834 - $134,033
-1,079 Reduced 12.26%
7,721 $952,000
Q4 2019

Feb 12, 2020
BUY
$64.27 - $86.37 $40,168 - $53,981
625 Added 7.65%
8,800 $744,000
Q3 2019

Nov 13, 2019
BUY
$67.4 - $85.11 $193,775 - $244,691
2,875 Added 54.25%
8,175 $551,000
Q2 2019

Aug 07, 2019
BUY
$80.35 - $93.9 $425,854 - $497,670
5,300 New
5,300 $454,000
Q2 2018

Aug 02, 2018
SELL
$76.01 - $99.03 $478,863 - $623,889
-6,300 Closed
0 $0
Q1 2018

May 14, 2018
SELL
$77.67 - $92.63 $54,369 - $64,841
-700 Reduced 10.0%
6,300 $511,000
Q4 2017

Feb 09, 2018
SELL
$80.76 - $95.13 $991,329 - $1.17 Million
-12,275 Reduced 63.68%
7,000 $624,000
Q3 2017

Nov 14, 2017
BUY
$80.6 - $94.95 $1.34 Million - $1.57 Million
16,575 Added 613.89%
19,275 $1.79 Million
Q2 2017

Aug 14, 2017
BUY
N/A
2,700
2,700 $245,000

Others Institutions Holding BMRN

# of Institutions
669
Shares Held
182M
Call Options Held
1.52M
Put Options Held
1.01M
View Full List

About BIOMARIN PHARMACEUTICAL INC

BMRN Quotes by TradingView
  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $10.2B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email